Navigation Links
MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
Date:1/13/2009

LONGMONT, Colo., Jan. 13 /PRNewswire/ -- A new bacterial identification test that rapidly identifies MRSA infections moved closer to market with conclusion of its first multicenter clinical trial, which was announced today by MicroPhage, Inc., http://www.microphage.com. The company also reported the trial results have surpassed its early-stage performance expectations.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/AQTU542)

The beta-site study evaluated MicroPhage's prototype assay to identify Staphylococcus aureus (staph) bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia (bacteria in the blood). The research precedes FDA-submission clinical studies, which are scheduled to begin early this year. Beta sites included Johns Hopkins University, Northshore University Healthcare (IL.), and the University of Maryland Medical School. More information on the study is available on the National Institute of Health's ClinicalTrials.gov website, study # NCT00814151.

According to Drew Smith, Ph.D, Director, Research and Development at MicroPhage, test performance at the three sites exceeded all study goals and performed at or near FDA requirements in more than 700 clinical samples. "Our prototype assay performed like a market-ready test for identification of MRSA, producing excellent results with regard to specificity," said Smith. "We are confident the final manufactured product will be robust and meet the demands of the clinical laboratory market and the scrutiny of the FDA." He added that the system is expected to be available to US hospitals later this year.

The field trials confirm previous performance studies reported in October at the prestigious joint meeting
'/>"/>

SOURCE MicroPhage, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
2. Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
3. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
6. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
7. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... ANA598 demonstrates favorable preclinical antiviral, metabolic, ... preliminary toxicologic properties, SAN DIEGO, Sept. 11 ... preclinical data today on ANA598, a,non-nucleoside inhibitor of ... the 14th International Symposium on Hepatitis C Virus ...
... have or have,ever had chronic heartburn, you may be ... severe gastroesophageal reflux disease,(GERD). Barrett,s esophagus has been recognized ... esophagus, the seventh deadliest cancer in men in,the United ... in the lining of the,esophagus, which can progress to ...
Cached Medicine Technology:Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer 2
(Date:4/24/2014)... of Manchester have identified a way to sensitise cancer ... treatment. , The study published today in Cell ... of drugs to target cells that have become resistant ... whilst exploring the possible mechanisms behind resistance to chemotherapy ... colon cancer. , Dr Andrew Gilmore, who led the ...
(Date:4/24/2014)... 2014 Scientific research at UT Southwestern Medical Center ... itself completely, whereas the adult heart lacks this ability. ... why the heart loses its incredible regenerative capability in ... , Yes, oxygen. It is well-known that a ... blood throughout the body. But at the same time, ...
(Date:4/24/2014)... coated with an antimicrobial peptide could help to lower the ... Optometry and Vision Science , official journal of ... is published by Lippincott Williams & Wilkins , a ... animals and now humans support the biocompatibility and safety of ... new research by Debarun Dutta, B.Optom, of The University of ...
(Date:4/24/2014)... DURHAM, N.C. Changes in managing patients before, during ... days and reduced readmission rates, according to researchers who ... Hospital. , The practice, called enhanced recovery, is easier ... period and bowel evacuation that are typically prescribed. After ... as soon as possible, leading to faster recoveries. , ...
(Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3
... thousands of elderly people in England have come under ... for Social Care Inspection many elderly people found their ... trust. ,The practice of giving 15 minute ... individual, was accused fo being "undignified and unsafe". The ...
... An HIV/AIDS vaccine has proved to be efficient on animals according ... ,"Perhaps we can cure HIV infection. This is our hope," said ... of the vaccine are expected soon with almost $5i million to ... this new medical revelation. ,Dr. Yong Kang said, ...
... have conducted a randomised, placebo controlled, double blind trial on ... the popular antiaging// supplement DHEA(dehydroepiandrosterone). The report published in the ... with the findings that DHEA cannot be considered the magic ... that the drug does not have any marked impact on ...
... effects of the country's worst epidemic of the mosquito-borne ... been infected by Chikungunya,// according to the World Health ... by the WHO, over 1.25 million suspected cases have ... is debilitating with severe joint pain and high fever. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... Hopkins have shown that transplanting human stem cells into ... disease delays the start of nerve// cell damage typical ... stem cells develop into nerve cells that make substantial ... to Lou Gehrig’s, also known as amyotrophic lateral sclerosis ...
Cached Medicine News:Health News:Standards of Home Care for Elderly Needs Change 2Health News:The Search For Eternal Youth-DHEA Not The Magic Potion 2Health News:45% of Indians Affected by Chikungunya Fever 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 3
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
... The Sysmex CA-7000 provides speed ... that is synonymous with Sysmex technology. ... CA-7000 offers throughput of up to ... hour in multi-parameter testing. This ...
... The Sysmex CA-1500 enhances productivity in the ... utilizes three detection methods clotting, chromogenic ... accurate and precise test results every time. ... communication options and random access, the CA-1500 ...
... is the lancing device that has set ... since 1983. This re-usable lancing device assists ... The auto-Lancet is constructed in the USA ... after day, year after year. It's the ...
Medicine Products: